Transforming lives with pioneering ocular gene therapy
Beacon Therapeutics is an ophthalmic gene therapy company founded to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
CEO Lance Baldo
Advent Contact Dominic Schmidt
Private Companies
Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Press Release. Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) To date, laru-zova has been well-tolerated…
Read More
Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer
Press Release. CEO Dave Fellows named non-Executive Chairman of the Board Executive appointments follow $170 million Series B fundraise London, UK and Cambridge, Mass., July 24, 2024 – Beacon…
Read More
